Second Sight Medical Products, Inc. (EYES)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.0300 |
| Open | 2.0100 |
| Bid | 1.9700 x 800 |
| Ask | 2.0500 x 1300 |
| Day's Range | 1.9851 - 2.0600 |
| 52 Week Range | 1.1400 - 4.2400 |
| Volume | |
| Avg. Volume | 273,988 |
| Market Cap | 80.395M |
| Beta (5Y Monthly) | 2.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3110 |
| Earnings Date | Jun 26, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Second Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual Meeting
LOS ANGELES, July 29, 2022--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held on July 27, 2022, where the quorum was present. The formal results of the vote are included in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission.
- Business Wire
Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study
LOS ANGELES, July 18, 2022--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prostheses that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company received notice from the National Institutes of Health ("NIH") of the release of year four funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (the "Orion Trial"), grant 5UH3NS103442.
- Business Wire
Nano Precision Medical Co-Founder and CEO Discusses Proposed Second Sight Merger in Interview to Air on Bloomberg U.S. on the RedChip Money Report®
LOS ANGELES, April 14, 2022--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight"), a recognized global leader in neuromodulation devices for blindness, today announced that an interview with Adam Mendelsohn, Ph.D., Co-Founder and CEO of Nano Precision Medical, Inc. ("NPM"), will air on The RedChip Money Report® on Bloomberg US on April 16 at 7 p.m. Eastern Time (ET). Bloomberg US is available in an estimated 73 million homes across the United States.
